Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

<p>Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary Dysmenorrhea SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced positive topline results from the Phase 1 study evaluating the pharmacokinetics (PK), safety, and exploratory efficacy of […]</p>
<p>The post <a href="https://forextv.com/top-news/dare-bioscience-announces-positive-topline-pharmacokinetic-and-exploratory-efficacy-results-from-the-dare-pdm1-phase-1-clinical-study/">Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>